Antisense oligonucleotides as therapeutic agents
- 23 September 1999
- journal article
- review article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 181 (2), 251-257
- https://doi.org/10.1002/(sici)1097-4652(199911)181:2<251::aid-jcp7>3.0.co;2-d
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention.Environmental Health Perspectives, 1999
- Antisense therapeuticsCurrent Opinion in Chemical Biology, 1998
- Antisense drugs move towards the clinicThe Lancet, 1997
- Synthetic Antisense Oligodeoxynucleotides as Potential Drugs against Hepatitis CIntervirology, 1997
- Antisense oligonucleotides: towards clinical trialsTrends in Biotechnology, 1996
- Progress in Antisense Oligonucleotide TherapeuticsAnnual Review of Pharmacology and Toxicology, 1996
- Modified oligonucleotides as therapeutic and diagnostic agentsCurrent Opinion in Biotechnology, 1995
- Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides.Journal of Clinical Investigation, 1995
- Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides.Journal of Clinical Investigation, 1994
- Cationic Lipids Improve Antisense Oligonucleotide Uptake and Prevent Degradation in Cultured Cells and in Human SerumBiochemical and Biophysical Research Communications, 1993